Beta 2-agonists as anti-inflammatory therapies in the lung.
The new generation of long-acting beta 2-agonists, represented by salmeterol and formoterol, inhibit a number of the processes involved in acute inflammation in the lung: inflammatory mediator release, vascular permeability and inflammatory cell accumulation. These effects arise from prolonged activation of beta 2-adrenoceptors in a range of target cells. Salmeterol and formoterol therefore have the potential to be used as additional anti-inflammatory therapy in the treatment of respiratory disease.
Johnson
M
M
Glaxo Group Research, Ware, U.K.
D000208:Acute Disease; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D001991:Bronchitis / Q000188:drug therapy; D002199:Capillary Permeability / Q000187:drug effects; D004983:Ethanolamines / Q000627:therapeutic use; D000068759:Formoterol Fumarate; D006801:Humans; D007249:Inflammation / Q000473:pathology; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate